Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on August 14, 2025. The filing serves to announce the company's unaudited financial results for the quarter ended June 30, 2025, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes in financial condition or operations are detailed in the body of this 8-K.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information regarding the financial results shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section. It is not incorporated by reference into other filings except as expressly set forth. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2025) for actual revenue, net income, and cash flow figures.
- Verify the unaudited nature of the reported results for the quarter ended June 30, 2025.
- Confirm the trading symbol (ICCC) and exchange (Nasdaq Capital Market) for the company's common stock.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act.